[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.197.142.219. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Research Letter
Health Care Reform
March 2016

Characteristics and Conflicts of Public Speakers at Meetings of the Oncologic Drugs Advisory Committee to the US Food and Drug Administration

Author Affiliations
  • 1Case Western Reserve University School of Medicine, Cleveland, Ohio
  • 2Division of Hematology Oncology/Knight Cancer Institute, Department of Public Health and Preventive Medicine, Center for Health Care Ethics, Oregon Health & Science University, Portland
JAMA Intern Med. 2016;176(3):389-391. doi:10.1001/jamainternmed.2015.7805

The Oncologic Drugs Advisory Committee advises the US Food and Drug Administration (FDA) about medications for the treatment of cancer. The committee’s meeting agenda typically includes presentations by both a company seeking marketing approval for an oncologic drug that it sponsors and by the FDA, as well as a public hearing for comments by other speakers. Speakers may be patients with cancer or may represent patient advocacy organizations, and speakers are asked to disclose financial associations with the sponsoring company or other relevant financial associations.

First Page Preview View Large
First page PDF preview
First page PDF preview
×